International Journal of Clinical Oncology

, Volume 23, Issue 1, pp 81–91 | Cite as

The use of neoadjuvant therapy for resectable locally advanced thoracic esophageal squamous cell carcinoma in an analysis of 5016 patients from 305 designated cancer care hospitals in Japan

  • Yoichiro Tsukada
  • Takahiro Higashi
  • Hideaki Shimada
  • Yoshinori Kikuchi
  • Atsuro Terahara
Original Article
  • 293 Downloads

Abstract

Background

Recent studies have shown the benefits of neoadjuvant therapy with chemotherapy or chemoradiotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC). The aim of our study was to elucidate the use of neoadjuvant therapy for thoracic ESCC in Japan.

Methods

Data on patients with stage IB–III thoracic ESCC were retrieved from the national database of hospital-based cancer registries combined with claims data between 2012 and 2013. These data were analyzed using a mixed-effect logistic regression analysis, with a focus on exploring patterns in the first-line treatment for ESCC, including proportion of patients who received neoadjuvant therapy, and investigating the hospital characteristics and patient factors associated with the use of neoadjuvant therapy.

Results

Of the 5016 patients with stage IB–III thoracic ESCC at the 305 participating hospitals, 34.2% received neoadjuvant therapy (neoadjuvant chemotherapy, 29.5%; neoadjuvant chemoradiotherapy, 4.7%). The therapy was less likely to be administered to older patients (≤64 years, 48.8%; 65–70 years, 42.0%; 70–75 years, 33.9%; 75–80 years, 22.2%; 80–85 years, 3.8%; ≥85 years, 1.4%) and at hospitals with a low volume of patients (very high, 42.1%; high, 37.5%; low, 30.7%; and very low, 26.4%). This trend was confirmed by regression analysis.

Conclusions

Based on our results, in Japan, relatively few patients with resectable locally advanced thoracic ESCC receive neoadjuvant therapy, with older patients and patients at lower volume hospitals being less likely than other patients to receive the neoadjuvant therapy. We recommend that the process of treatment decision-making be assessed at both the patient and hospital levels so that patients can consider various treatment options, including neoadjuvant therapy with surgery in Japan.

Keywords

Esophageal cancer Practice patterns Healthcare inequalities Registries Age Hospital volume 

Notes

Acknowledgements

We thank Kaoru Konno for her technical assistance for this project, as well as the participating hospitals that submitted insurance claim data. This work was supported by the National Cancer Center Research and Development Programs (Grant Number 28–A–21).

Compliance with ethical standards

Conflict of interest

No conflict of interest.

Supplementary material

10147_2017_1178_MOESM1_ESM.docx (48 kb)
Supplementary material 1 (DOCX 48 kb)

References

  1. 1.
    Ferlay J SI, Ervik M, Dikshit R, et al. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr. Accessed July 2016
  2. 2.
    Ando N, Iizuka T, Ide H, et al. (2003) Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol 21(24):4592–4596CrossRefPubMedGoogle Scholar
  3. 3.
    Ando N, Kato H, Igaki H, et al. (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68–74CrossRefPubMedGoogle Scholar
  4. 4.
    Shapiro J, van Lanschot JJ, Hulshof MC, et al. (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16:1090–1098CrossRefPubMedGoogle Scholar
  5. 5.
    The Japan Esophageal Society (2012) Guidelines for diagnosis and treatments of esophageal cancer. Kanehara Co. Ltd, Tokyo (in Japanese)Google Scholar
  6. 6.
    The National Comprehensive Cancer Network (2016) Esophageal and esophagogastric junction cancers, ver 2, 2016. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed Sept 2016
  7. 7.
    Lordick F, Mariette C, Haustermans K, et al. (2016) Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v50–v57CrossRefPubMedGoogle Scholar
  8. 8.
    Little AG, Lerut AE, Harpole DH, et al. (2014) The Society of Thoracic Surgeons practice guidelines on the role of multimodality treatment for cancer of the esophagus and gastroesophageal junction. Ann Thorac Surg 98:1880–1885CrossRefPubMedGoogle Scholar
  9. 9.
    Molena D, Mungo B, Stem M, et al. (2015) Does quality of care matter? A study of adherence to national comprehensive cancer network guidelines for patients with locally advanced esophageal cancer. J Gastrointest Surg 19:1739–1747CrossRefPubMedGoogle Scholar
  10. 10.
    Suntharalingam M, Moughan J, Coia LR, et al. (2005) Outcome results of the 1996–1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. J Clin Oncol 23:2325–2331CrossRefPubMedGoogle Scholar
  11. 11.
    Smith GL, Smith BD, Buchholz TA, et al. (2009) Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: the SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys 74:482–489CrossRefPubMedGoogle Scholar
  12. 12.
    Steyerberg EW, Neville B, Weeks JC, et al. (2007) Referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol 25:2389–2396CrossRefPubMedGoogle Scholar
  13. 13.
    Molena D, Stem M, Blackford AL, et al. (2017) Esophageal cancer treatment is underutilized among elderly patients in the USA. J Gastrointest Surg 21:126–136CrossRefPubMedGoogle Scholar
  14. 14.
    Healy MA, Yin H, Wong SL (2016) Multimodal cancer care in poor prognosis cancers: resection drives long-term outcomes. J Surg Oncol 113:599–604CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Tachimori Y, Ozawa S, Numasaki H, et al. (2016) Comprehensive registry of esophageal cancer in Japan, 2009. Esophagus 13:110–137CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Cancer Information Surveillance Division, Center for Cancer Control and Information Services. National Cancer Center (2016) the Report of Hospital-Based Cancer Registry from Designated Cacner Center Hospitals in Japan 2014. http://ganjoho.jp/data/reg_stat/statistics/brochure/2014_report.pdf. Accessed April 2017 (in Japanese)
  17. 17.
    Iwamoto M, Nakamura F, Higashi T (2016) Monitoring and evaluating the quality of cancer care in Japan using administrative claims data. Cancer Sci 107:68–75CrossRefPubMedGoogle Scholar
  18. 18.
    Higashi T, Nakamura F, Shibata A, et al. (2014) The national database of hospital-based cancer registries: a nationwide infrastructure to support evidence-based cancer care and cancer control policy in Japan. Jpn J Clin Oncol 44:2–8CrossRefPubMedGoogle Scholar
  19. 19.
    Nakamura K, Kato K, Igaki H, et al. (2013) Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol 43:752–755CrossRefPubMedGoogle Scholar
  20. 20.
    van Hagen P, Hulshof MC, van Lanschot JJ, et al. (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084CrossRefPubMedGoogle Scholar
  21. 21.
    Burmeister BH, Smithers BM, Gebski V, et al. (2005) Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6:659–668CrossRefPubMedGoogle Scholar
  22. 22.
    Bradley JD, Paulus R, Graham MV, et al. (2005) Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group—RTOG 9705. J Clin Oncol 23:3480–3487CrossRefPubMedGoogle Scholar
  23. 23.
    Kato K, Muro K, Minashi K, et al. (2011) Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 81:684–690CrossRefPubMedGoogle Scholar
  24. 24.
    Lester SC, Lin SH, Chuong M, et al. (2017) A multi-institutional analysis of trimodality therapy for esophagus cancer in elderly patients. Int J Radiat Oncol Biol Phys 98:820–828Google Scholar
  25. 25.
    Pultrum BB, Bosch DJ, Nijsten MW, et al. (2010) Extended esophagectomy in elderly patients with esophageal cancer: minor effect of age alone in determining the postoperative course and survival. Ann Surg Oncol 17:1572–1580CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Ruol A, Portale G, Zaninotto G, et al. (2007) Results of esophagectomy for esophageal cancer in elderly patients: age has little influence on outcome and survival. J Thorac Cardiovasc Surg 133:1186–1192CrossRefPubMedGoogle Scholar
  27. 27.
    Sylvie L, Silvia S, Salah-Eddin AB, et al. (2015) Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer. Eur J Cancer 51:1918–1926CrossRefPubMedGoogle Scholar
  28. 28.
    Fogh SE, Yu A, Kubicek GJ, et al. (2011) Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy? Int J Radiat Oncol Biol Phys 80:1372–1376CrossRefPubMedGoogle Scholar
  29. 29.
    Hamamoto Y, Akutsu Y, Nagashima F, et al. (2016) Multicenter questionnaire survey on patterns of care for elderly patients with esophageal squamous cell carcinoma by the Japan Esophageal Oncology Group. Jpn J Clin Oncol 46:111–115CrossRefPubMedGoogle Scholar
  30. 30.
    Brannstrom F, Bjerregaard JK, Winbladh A, et al. (2015) Multidisciplinary team conferences promote treatment according to guidelines in rectal cancer. Acta Oncol 54:447–453CrossRefPubMedGoogle Scholar
  31. 31.
    Fujita H, Ozawa S, Kuwano H, et al. (2010) Esophagectomy for cancer: clinical concerns support centralizing operations within the larger hospitals. Dis Esophagus 23:145–152CrossRefPubMedGoogle Scholar
  32. 32.
    Munasinghe A, Markar SR, Mamidanna R, et al. (2014) Is it time to centralize high-risk cancer care in the United States? Comparison of outcomes of esophagectomy between England and the United States. Ann Surg 262:79–85CrossRefGoogle Scholar
  33. 33.
    Shimada H, Fukagawa T, Haga Y, et al. (2017) Does postoperative morbidity worsen the oncological outcome after radical surgery for gastrointestinal cancers? A systematic review of the literature. Ann Gastroenterol Surg 1:11–23CrossRefGoogle Scholar
  34. 34.
    Speicher PJ, Ganapathi AM, Englum BR, et al. (2014) Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. J Thorac Oncol 9:1195–1201CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Markar SR, Gronnier C, Pasquer A, et al. (2016) Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study. Eur J Cancer 56:59–68CrossRefPubMedGoogle Scholar
  36. 36.
    Wong IY-H, Law S (2016) Surgery in the era of neoadjuvant therapy for cancer of the esophagus. Esophagus 13(2):105–109CrossRefGoogle Scholar
  37. 37.
    Sjoquist KM, Burmeister BH, Smithers BM, et al. (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692CrossRefPubMedGoogle Scholar
  38. 38.
    Kranzfelder M, Schuster T, Geinitz H, et al. (2011) Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg 98:768–783CrossRefPubMedGoogle Scholar
  39. 39.
    Ikegami N, Yoo BK, Hashimoto H, et al. (2011) Japanese universal health coverage: evolution, achievements, and challenges. Lancet 378:1106–1115CrossRefPubMedGoogle Scholar
  40. 40.
    World Health Organization (WHO) and Ministry of Health, Labour and Welfare, Japan (2012) Health Service Delivery Profile Japan 2012. http://www.wpro.who.int/health_services/service_delivery_profile_japan.pdf. Accessed July 2017
  41. 41.
    Victoor A, Delnoij DM, Friele RD, et al. (2012) Determinants of patient choice of healthcare providers: a scoping review. BMC Health Serv Res 12:272CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Al-Refaie WB, Muluneh B, Zhong W, et al. (2012) Who receives their complex cancer surgery at low-volume hospitals? J Am Coll Surg 214:81–87CrossRefPubMedGoogle Scholar
  43. 43.
    Zhang J, Peng F, Li N, et al. (2012) Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer. Radiat Oncol 7:93CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Yoo C, Park JH, Yoon DH, et al. (2012) Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer. Ann Thorac Surg 94:1862–1868CrossRefPubMedGoogle Scholar
  45. 45.
    Center for Cancer Control and Information Services, National Cancer Center (2015) Current cancer statistics. http://ganjoho.jp/reg_stat/statistics/stat/summary.html. Accessed Jan 2017 (in Japanese)

Copyright information

© Japan Society of Clinical Oncology 2017

Authors and Affiliations

  1. 1.Division of Health Services Research, Center for Cancer Control and Information ServicesNational Cancer CenterTokyoJapan
  2. 2.Department of RadiologyToho University Omori Medical CenterTokyoJapan
  3. 3.Department of Clinical OncologyToho University Graduate School of MedicineTokyoJapan
  4. 4.Department of Surgery, Faculty of MedicineToho UniversityTokyoJapan
  5. 5.Division of Gastorenterology and Hepatology, Department of Internal Medicine, Faculty of MedicineToho UniversityTokyoJapan

Personalised recommendations